Regulatory

Zealand Pharma gets European Commission nod for first major SBS treatment advance in decade

  • By IPP Bureau | November 16, 2026
Zealand Pharma has secured European Commission approval for Zeydovio (glepaglutide), a next-generation, long-acting GLP-2 analogue for treating adults with short bowel syndrome (SBS).
 
This marks a major regulatory breakthrough for patients living with the debilitating condition.
 
The marketing authorisation, announced by the Danish biotechnology company, is valid across all European Union member states, as well as Iceland, Liechtenstein and Norway.
 
The approval represents the first major advancement in short bowel syndrome treatment in more than a decade, according to the company, and brings a new twice-weekly treatment option to adults affected by the condition.
 
“The European Commission’s approval of Zeydovio is an important milestone for people living with short bowel syndrome in Europe, and the first major advancement in treatment in more than a decade. Zeydovio combines proven efficacy with simple twice-weekly dosing, and it has the potential to meaningfully ease the burden of this disease,” said Adam Steensberg, President and Chief Executive Officer of Zealand Pharma.
 
“With this regulatory approval, our focus now turns to finding the right partner to bring ZeydovioTM to as many people living with short bowel syndrome as possible across Europe and beyond, and to further advance the ongoing Phase 3 EASE-5 trial to support U.S. registration.”
 
The European approval is backed by results from the pivotal Phase 3 EASE-1 trial, in which twice-weekly glepaglutide demonstrated a statistically significant and superior reduction in parenteral support requirements compared with placebo among patients with short bowel syndrome and intestinal failure.
 
Additional evidence came from interim data from the EASE-2 and EASE-3 extension trials, which are following patients for up to two years, and the mechanistic EASE-4 trial, which demonstrated improved intestinal absorption with glepaglutide.
 
Across its clinical development programme, glepaglutide has so far shown a safety and tolerability profile that the company describes as favourable. Full results from EASE-2 and EASE-3, expected to confirm long-term efficacy and safety, are scheduled for presentation at scientific meetings in 2027.
 
With European regulatory clearance secured, Zealand Pharma is now looking to accelerate the drug's commercial reach. The company is actively holding partnership discussions to identify a partner for the future global commercialisation of glepaglutide.
 
Meanwhile, its US regulatory ambitions remain on track, with the Phase 3 EASE-5 trial continuing to generate additional confirmatory evidence intended to support a US regulatory submission. Patient recruitment is progressing well, the company said.
 
The European approval gives Zealand Pharma a significant regulatory foothold in the treatment of short bowel syndrome, while the ongoing US clinical programme and global partnership discussions will be key to determining the drug's wider commercial potential.

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.